SCHEMBL17491446

SCHEMBL17491446

N#Cc1cc(NC(=O)c2cccc(Cl)c2)cc(-c2cnco2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.51
▸ NPC1 O15118 2/20 0.51
▸ PKM P14618 2/20 0.51
▸ LMNA P02545 2/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ LCLAT1 Q6UWP7 1/20 0.48
▸ KCNQ3 O43525 2/20 0.47
▸ KCNQ2 O43526 2/20 0.47
▸ KCNE1 P15382 2/20 0.47
▸ KCNQ1 P51787 2/20 0.47
▸ KCNQ5 Q9NR82 1/20 0.47
▸ MEN1 O00255 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ TDP1 Q9NUW8 2/20 0.46
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17491381 0.87 NPC1 (0.57) KDM4ENPC1PKMLMNAALDH1A1
SCHEMBL17491464 0.82 NPC1 (0.51) KDM4ENPC1PKMLMNAALDH1A1
SCHEMBL17491475 0.82 P2RX1 (0.51) KDM4ENPC1PKMLMNAALDH1A1
SCHEMBL17491421 0.81 KDM4E (0.50) KDM4ENPC1PKMLMNAALDH1A1
SCHEMBL17491543 0.78 CYP3A4 (0.56) PKMLMNAKMT2ATDP1CYP3A4
SCHEMBL12412651 0.74 GRM5 (0.71) CYP3A4GRM5
SCHEMBL17491426 0.74 DYRK1A (0.51) KDM4ECYP1A2CYP3A4CYP2C9
SCHEMBL12412648 0.73 GRM5 (0.72) MEN1KMT2AGRM5
SCHEMBL17491492 0.71 ROCK2 (0.46) KDM4ENPC1PKMLMNAALDH1A1
SCHEMBL17491467 0.69 KDM4E (0.66) KDM4ENPC1PKMLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2982670-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2018-11-07 — — EP disclosed
US-9624184-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-04-18 — — US disclosed
US-9624184-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-04-18 — — US disclosed
US-9624184-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-04-18 — — US disclosed
US-20160052897-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-02-25 — — US disclosed
EP-2982670-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed
EP-2982670-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052897-A1 HETEROCYCLIC COMPOUND PSEN1, PSEN2, BACE1 KDM4E 764/4885NPC1 498/4885PKM 1648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback